Literature DB >> 2971460

Monoclonal antibody internalization and degradation during modulation of the CD3/T-cell receptor complex.

L Schaffar1, A Dallanegra, J P Breittmayer, S Carrel, M Fehlmann.   

Abstract

Although it is well known that the CD3/T-cell receptor (TCR) complex modulates from the surface of T cells upon exposure to monoclonal antibodies (mAb) directed against it, the fate of bound mAb has not been yet elucidated. We therefore perform direct binding experiments of 125I-labeled mAb against CD3 or TCR to investigate their fate in Jurkat T cells. We demonstrated that all mAb were progressively internalized and degraded in Jurkat T cells and that this degradation was inhibited by chloroquine, an inhibitor of lysosomal degradation enzymes. The sequestration of anti-CD3 mAb in acid compartments was furthermore shown using cytofluorometry. All together our results show that antibodies against CD3 or against TCR follow the same endocytic pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971460     DOI: 10.1016/0008-8749(88)90209-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2.

Authors:  C R Carter; B W Hancock; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Quantification of Antibody Persistence for Cell Surface Protein Labeling.

Authors:  Megan E Dempsey; Olivia Woodford-Berry; Eric M Darling
Journal:  Cell Mol Bioeng       Date:  2021-04-20       Impact factor: 2.321

3.  CD6 is a target for cancer immunotherapy.

Authors:  Jeffrey H Ruth; Mikel Gurrea-Rubio; Kalana S Athukorala; Stephanie M Rasmussen; Daniel P Weber; Peggy M Randon; Rosemary J Gedert; Matthew E Lind; M Asif Amin; Phillip L Campbell; Pei-Suen Tsou; Yang Mao-Draayer; Qi Wu; Thomas M Lanigan; Venkateshwar G Keshamouni; Nora G Singer; Feng Lin; David A Fox
Journal:  JCI Insight       Date:  2021-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.